Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120)

被引：0
|
作者：
Zukin, M. [1 ]
Gelatti, A. C. Z. [2 ]
Gondim, V. [3 ]
Shimada, A. K. [4 ]
Magalhaes, E. [5 ]
Mathias, C. [6 ]
Barra, W. F. [7 ]
William Junior, W. N. [8 ]
Padoan, M. [3 ]
Bittencourt, Y. [4 ]
Yamamura, R. [8 ]
Gossling, G. [9 ]
Rebelatto, T. F. [9 ]
de Jesus, R. G. [9 ]
Silva, C. E. B. [10 ]
机构：
[1] Oncol & Inst, Sao Paulo, Brazil
[2] CPO Porto Alegre, Porto Alegre, RS, Brazil
[3] Inst Amer, Rio De Janeiro, Brazil
[4] Hosp Sirio Libanes, Sao Paulo, SP, Brazil
[5] Inst Mario Penna, Belo Horizonte, MG, Brazil
[6] Oncoclin BA & Hosp Santa Izabel, Salvador, BA, Brazil
[7] Univ Fed Nucl Pesquisa Oncol, Belem, Para, Brazil
[8] BP A Beneficencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil
[9] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[10] Hosp Canc Barretos, Barretos, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-Small Cell Lung Cancer; Durvalumab; Brazil;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-30
引用
收藏
页码：S582 / S582
页数：1
相关论文
共 50 条
  • [21] Dynamic Blood Count Changes in Patients with unresectable Stage III NSCLC on Durvalumab Maintenance Therapy after completed Radiochemotherapy
    Guggenberger, J.
    Kenndoff, S.
    Taugner, J.
    Kasmann, L.
    Florsch, B.
    Tufman, A.
    Reinmuth, N.
    Belka, C.
    Eze, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S107 - S108
  • [22] Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
    Ozguroglu, M.
    Levy, B.
    Horinouchi, H.
    Yu, J.
    Grainger, E.
    Phuong, P.
    Peterson, D. A.
    Newton, M.
    Spira, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S991 - S991
  • [23] 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study
    de Wit, M.
    Spigel, D.
    Faivre-Finn, C.
    Gray, J.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J.
    Garassino, M.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L.
    Ozguroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S8 - S9
  • [24] Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
    Garassino, Marina C.
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Bischoff, Helge
    Reinmuth, Niels
    Cove-Smith, Laura
    Mansy, Talal
    Cortinovis, Diego
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1415 - 1427
  • [25] Safety and Efficacy Results of Durvalumab following Sequential Chemoradiotherapy (sCRT) in Unresectable Stage III NSCLC (PACIFIC 6)
    Heilmann, M.
    Garassino, M. C.
    Mazieres, J.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L.
    Mansy, T.
    Cortinovis, D.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. G.
    Velarde, L. E. C.
    Bernabe, R.
    Paz-Ares, L.
    Perez, Diaz, I
    Trunova, N.
    Foroutanpour, K.
    Faivre-Finn, C.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 97 - 98
  • [26] 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial
    de Wit, M.
    Spigel, D. R.
    Faivre-Finn, C.
    Gray, J. E.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Garassino, M. C.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L
    Oezgueroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S. J.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 109 - 110
  • [27] First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC
    Faehling, Martin
    Planchard, David
    Cho, Byoung Chul
    Gray, Jhanelle Elaine
    Paz-Ares, Luis G.
    Ozguroglu, Mustafa
    Villegas, Augusto E.
    Daniels, Davey B.
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Gu, Yu
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott Joseph
    de Wit, Maike
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
  • [28] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
    Park, Cheol-Kyu
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Jeong, Won Gi
    Lee, Jeong Yeop
    Lee, Jae Cheol
    Choi, Chang Min
    Ji, Wonjun
    Song, Si Yeol
    Choi, Juwhan
    Lee, Sung Yong
    Kim, Hakyoung
    Lee, Shin Yup
    Park, Jongmoo
    Yoon, Seong Hoon
    Joo, Ji Hyeon
    Oh, In-Jae
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054
  • [29] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Girard, N.
    Mornex, F.
    Christoph, D. C.
    Fietkau, R.
    Filippi, A. R.
    Field, J.
    Garrido Lopez, P.
    McDonald, F.
    Peters, S.
    Klein, A. B.
    Licour, M.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Christoph, D. C.
    Behringer, D.
    Emde, T. O.
    Goekkurt, E.
    Laack, E.
    Mueller-Huesmann, H.
    Schuett, P.
    Schumann, C.
    Seese, B.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
12345